We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can-Fite said about one-third of patients were alive at data cutoff as survival follow-up continues.
Can-Fite BioPharma (CANF - Free Report) shares soared 20.4% on Wednesday after the company reported positive top-line results from a mid-stage study of its investigational candidate, namodenoson, in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had progressed following prior systemic therapies.
Can-Fite’s namodenoson is a highly selective A3AR agonist, which has previously demonstrated a strong safety profile and anti-tumor activity in preclinical models of pancreatic cancer.
More on CANF’s Mid-stage Pancreatic Cancer Study Results
Can-Fite’s phase IIa study of namodenoson enrolled 20 patients with advanced PDAC who had received at least one prior line of therapy, representing a high-risk group with varying performance status and advanced metastatic disease.
Per the data readout, the mid-stage study met its primary safety endpoint, with namodenoson demonstrating strong tolerability in a heavily pretreated population of PDAC patients. No new safety concerns were reported during the study, and the observed safety profile remained consistent with prior clinical findings for the drug candidate across other oncology indications.
In the past six months, Can-Fite shares have plunged 54% compared with the industry’s 9% decline.
Image Source: Zacks Investment Research
Beyond safety, the study also evaluated key secondary endpoints, including overall survival and progression-free survival. Survival monitoring is ongoing, and at the time of the data cut-off, roughly one-third of the enrolled patients were still alive. Continued follow-up is expected to provide a clearer picture of long-term survival outcomes.
As additional data matures, the company plans to share updated survival findings at upcoming scientific conferences. The encouraging safety profile in this difficult-to-treat patient group supports further clinical evaluation of namodenoson in pancreatic cancer. The candidate enjoys the FDA’s Orphan Drug designation in the United States for the treatment of pancreatic cancer.
Apart from PDAC, Can-Fite is also simultaneously evaluating namodenoson in a late-stage study for advanced liver cancer (hepatocellular carcinoma) and in a mid-stage study for metabolic-associated steatohepatitis.
Can-Fite’s clinical pipeline also comprises its lead candidate, piclidenoson, which is currently being evaluated in a pivotal late-stage study for the treatment of psoriasis.
Over the past 60 days, estimates for USANA Health Sciences’ 2026 earnings per share (EPS) have risen from $1.90 to $2.00. USNA shares have lost 37.5% over the past six months.
USANA Health Sciences’ earnings beat estimates in three of the trailing four quarters and matched once, with the average surprise being 21.92%.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have risen from $2.54 to $2.82. CPRX shares have soared 22.9% over the past six months.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ALX Oncology Holdings’ 2026 loss per share have narrowed from $1.21 to 88 cents. ALXO shares have rallied 97.3% over the past six months.
ALX Oncology Holdings’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 12.82%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Key Takeaways
Can-Fite BioPharma (CANF - Free Report) shares soared 20.4% on Wednesday after the company reported positive top-line results from a mid-stage study of its investigational candidate, namodenoson, in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had progressed following prior systemic therapies.
Can-Fite’s namodenoson is a highly selective A3AR agonist, which has previously demonstrated a strong safety profile and anti-tumor activity in preclinical models of pancreatic cancer.
More on CANF’s Mid-stage Pancreatic Cancer Study Results
Can-Fite’s phase IIa study of namodenoson enrolled 20 patients with advanced PDAC who had received at least one prior line of therapy, representing a high-risk group with varying performance status and advanced metastatic disease.
Per the data readout, the mid-stage study met its primary safety endpoint, with namodenoson demonstrating strong tolerability in a heavily pretreated population of PDAC patients. No new safety concerns were reported during the study, and the observed safety profile remained consistent with prior clinical findings for the drug candidate across other oncology indications.
In the past six months, Can-Fite shares have plunged 54% compared with the industry’s 9% decline.
Image Source: Zacks Investment Research
Beyond safety, the study also evaluated key secondary endpoints, including overall survival and progression-free survival. Survival monitoring is ongoing, and at the time of the data cut-off, roughly one-third of the enrolled patients were still alive. Continued follow-up is expected to provide a clearer picture of long-term survival outcomes.
As additional data matures, the company plans to share updated survival findings at upcoming scientific conferences. The encouraging safety profile in this difficult-to-treat patient group supports further clinical evaluation of namodenoson in pancreatic cancer. The candidate enjoys the FDA’s Orphan Drug designation in the United States for the treatment of pancreatic cancer.
Apart from PDAC, Can-Fite is also simultaneously evaluating namodenoson in a late-stage study for advanced liver cancer (hepatocellular carcinoma) and in a mid-stage study for metabolic-associated steatohepatitis.
Can-Fite’s clinical pipeline also comprises its lead candidate, piclidenoson, which is currently being evaluated in a pivotal late-stage study for the treatment of psoriasis.
Can-Fite Biopharma Ltd Price and Consensus
Can-Fite Biopharma Ltd price-consensus-chart | Can-Fite Biopharma Ltd Quote
CANF’s Zacks Rank and Stocks to Consider
Can-Fite currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are USANA Health Sciences (USNA - Free Report) , Catalyst Pharmaceuticals (CPRX - Free Report) and ALX Oncology Holdings (ALXO - Free Report) . While USNA and CPRX sport a Zacks Rank #1 (Strong Buy) each, ALXO carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for USANA Health Sciences’ 2026 earnings per share (EPS) have risen from $1.90 to $2.00. USNA shares have lost 37.5% over the past six months.
USANA Health Sciences’ earnings beat estimates in three of the trailing four quarters and matched once, with the average surprise being 21.92%.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have risen from $2.54 to $2.82. CPRX shares have soared 22.9% over the past six months.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ALX Oncology Holdings’ 2026 loss per share have narrowed from $1.21 to 88 cents. ALXO shares have rallied 97.3% over the past six months.
ALX Oncology Holdings’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 12.82%.